The Hippo signaling pathway provides novel anti-cancer drug targets

Area of Science:

• Cell Biology
• Molecular Biology
• Oncology

Background:

• The Hippo signaling pathway regulates fundamental cellular processes like proliferation and apoptosis.
• Key effectors Yes-associated protein 1 (YAP) and WW domain-containing transcription regulator protein 1 (TAZ) are central to this pathway.
• YAP and TAZ activity is influenced by diverse signaling networks and the cellular microenvironment.

Purpose of the Study:

• To review signaling networks interacting with the Hippo pathway.
• To explore the role of Hippo signaling dysregulation in cancer development.
• To discuss the therapeutic potential of inhibiting YAP and TAZ in cancer.

Main Methods:

• Literature review of signaling pathways interacting with Hippo.
• Analysis of YAP and TAZ roles in oncogenesis.
• Evaluation of drug-targeting strategies for YAP and TAZ.

Main Results:

• Hippo pathway dysregulation, particularly high YAP and TAZ activity, is linked to numerous cancer types.
• Various biological factors, including mechanical stress and other signaling pathways, synergize with Hippo components to promote oncogenesis.
• Interactions with pathways like GPCR, EGFR, Wnt, Notch, and TGF-β/BMP influence Hippo signaling.

Conclusions:

• The Hippo signaling pathway is a critical regulator of cell fate and development.
• Functional disruption of Hippo signaling enhances oncogenic YAP and TAZ activities, driving cancer progression.
• Inhibiting YAP and TAZ presents a promising therapeutic strategy for cancer treatment.